Preclinical Pharmacokinetics and Dosimetry Studies of 124I/131I-CLR1404 for Treatment of Pediatric Solid Tumors in Murine Xenograft Models

Conclusion: CLR1404 is a suitable theranostic scaffold for dosimetry and therapy with potentially broad applicability in pediatric oncology. Given the ongoing clinical trials for CLR 131 in adults, these data support the development of pediatric clinical trials and provide detailed dosimetry that may lead to improved MRT treatment planning.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Basic Source Type: research

Related Links:

Abstract Over the past decades, studies of phytochemicals as modifiers of radiotherapeutic efficacy have become increasingly popular to improve the treatment outcome of human malignancies. In the current comprehensive review article, radiosensitizing effects of curcumin, a yellow-colored polyphenolic constituent of turmeric, in various preclinical cancer models, both In Vitro and In Vivo, are presented. Attenuation of radioadaptation and augmentation of irradiation-induced cancer cell killing are achieved through multifaceted action of curcumin on suppression of prosurvival and antiapoptotic factors. Mos...
Source: Nutrition and Cancer - Category: Cancer & Oncology Authors: Tags: Nutr Cancer Source Type: research
CONCLUSION: Prexasertib has significant anti-tumor effects as a monotherapy or in combination with chemotherapy in multiple preclinical models of pediatric cancer. These findings support further investigation of prexasertib in pediatric malignancies. PMID: 30563935 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Objective: Cancer mortality is a leading cause of disease-related death in the adolescent and young adult (AYA) population. Compared with older and younger patients, AYA patients often experience worse cancer-specific outcomes. Here, we compare AYA and pediatric overall survival (OS) in the most common pediatric extracranial solid tumors. Materials and Methods: Using the US Surveillance, Epidemiology, and End Results database, we studied patients (age, 0 to 39 y) diagnosed with Ewing sarcoma, neuroblastoma, osteosarcoma, rhabdomyosarcoma, and Wilms tumor. Results: A total of 12,375 patients (age, 0 to 39 y) were di...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Pediatric Source Type: research
Conditions:   Pediatric Solid Tumor;   Pediatric Lymphoma;   Pediatric Brain Tumor Intervention:   Drug: CLR 131 Sponsor:   Cellectar Biosciences, Inc. Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Abstract BackgroundOntuxizumab is a humanized IgG monoclonal antibody that targets the cell‐surface glycoprotein endosialin (tumor endothelial marker‐1[TEM‐1]/CD248) found on activated mesenchymal cells and certain tumors. Ontuxizumab binding to endosialin may interfere with platelet‐derived growth factor signaling, prevent tumor stroma organization, and prevent new vessel formation. MethodsOntuxizumab was administered intravenously on days 1, 8, 15, and 22 of a 28‐day cycle at three dose levels (4, 8, and 12 mg/kg). Further dose escalation to 16 mg/kg was planned if the maximum tolerated dose (MTD) was...
Source: Pediatric Blood and Cancer - Category: Cancer & Oncology Authors: Tags: RESEARCH ARTICLE Source Type: research
In this study, we reviewed 25 patients diagnosed with a spinal metastasis of unknown primary who presented with low back pain or acute-onset neurologic deficits and underwent operative treatment.
Source: World Neurosurgery - Category: Neurosurgery Authors: Tags: Original Article Source Type: research
More News: Bone Cancers | Brain | Cancer | Cancer & Oncology | Child Development | Children | Clinical Trials | Ewing's Sarcoma | External Beam Therapy | Neuroblastoma | Neurology | Nuclear Medicine | Pediatrics | Rhabdomyosarcoma | Sarcomas | Study